Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.
Approval Alert | Zanubrutinib Tablets in Multiple Hematologic Indications
Advertisement
Advertisement
Trending on CancerNetwork
1
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
2
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
3
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
4
Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC
5
